Pure Biologics

Pure Biologics Liabilities

The The Liabilities of Pure Biologics (PUR.WA) as of Oct 8, 2026 is 19.09 M PLN. In the previous year, The Liabilities was 15.46 M PLN — a change of 23.47% (higher).

Liabilities

19.09 MPLN

YoY

23.47%

Last updated:

In 2025, Pure Biologics's total liabilities amounted to 19.09 M PLN, a 23.47% difference from the 15.46 M PLN total liabilities in the previous year.

The Pure Biologics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
4.36 M PLN
Jan 1, 2019
14.57 M PLN
Jan 1, 2020
21.83 M PLN
Jan 1, 2021
7.70 M PLN
Jan 1, 2022
14.71 M PLN
Jan 1, 2023
20.85 M PLN
Jan 1, 2024
15.46 M PLN
Jan 1, 2025
19.09 M PLN
The Pure Biologics Liabilities history
YEARLiabilitiesYoY
19.09 MPLN+23.47%
15.46 MPLN-25.84%
20.85 MPLN+41.69%
14.71 MPLN+90.97%
7.70 MPLN-64.71%
21.83 MPLN+49.80%
14.57 MPLN+234.41%
4.36 MPLN+290.25%
1.12 MPLN+74.43%
640,124.00PLN—
Access this data via the Eulerpool API
Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Pure Biologics's Liabilities

Pure Biologics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pure Biologics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pure Biologics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pure Biologics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pure Biologics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pure Biologics stock

The Liabilities of Pure Biologics is 19.09 M PLN in 2025.

The Liabilities of Pure Biologics changed from 15.46 M PLN to 19.09 M PLN, representing a 23.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Pure Biologics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Pure Biologics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pure Biologics